How should muscle disorders be classified?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Classification of Muscle Disorders

Muscle disorders should be classified into two major categories—acquired and inherited—with further subdivision based on underlying pathogenic mechanisms including inflammatory, metabolic, structural, mitochondrial, and neuromuscular junction disorders 1, 2.

Primary Classification Framework

Acquired vs. Inherited Division

The fundamental distinction separates:

  • Acquired myopathies: Generally treatable, including inflammatory, toxic, endocrine, infectious, and critical illness myopathies
  • Inherited myopathies: Increasingly treatable with targeted molecular therapies, including muscular dystrophies, congenital myopathies, metabolic myopathies, and channelopathies 1

Mechanistic Classification System

Modern classification prioritizes pathophysiological mechanisms over purely clinical phenotypes 2:

1. Inflammatory Myopathies (Idiopathic Inflammatory Myopathies)

The 2017 EULAR/ACR criteria provide the most robust classification framework for this category 3. These use a weighted scoring system incorporating:

  • Age of onset (18-40 years: 1.3-1.5 points; ≥40 years: 2.1-2.2 points)
  • Muscle weakness patterns (proximal symmetric weakness, neck flexor predominance)
  • Skin manifestations (heliotrope rash: 3.1-3.2 points; Gottron's papules/sign: 2.1-3.7 points)
  • Laboratory findings (Anti-Jo-1 antibody: 3.8-3.9 points; elevated CK/LDH/AST/ALT: 1.3-1.4 points)
  • Muscle biopsy features (endomysial infiltration, perifascicular atrophy, rimmed vacuoles)

A total score ≥5.5 (without biopsy) or ≥6.7 (with biopsy) indicates "probable IIM" with 87%/82% sensitivity/specificity (93%/88% with biopsy) 3. Major subgroups include polymyositis (PM), dermatomyositis (DM), juvenile dermatomyositis (JDM), inclusion body myositis (IBM), immune-mediated necrotizing myopathy (IMNM), and antisynthetase syndrome.

2. Structural Myopathies

Primarily muscular dystrophies characterized by progressive muscle necrosis, atrophy, and replacement with fat/connective tissue 4. Classification based on defective proteins:

  • Dystrophinopathies (Duchenne, Becker)
  • Limb-girdle muscular dystrophies (LGMD) - classified by genetic defect and protein abnormality 5
  • Facioscapulohumeral dystrophy
  • Myotonic dystrophy
  • Collagen VI-related myopathies 6
  • Emery-Dreifuss muscular dystrophies 6

3. Metabolic Myopathies

Disorders of energy metabolism 4, 1:

  • Glycogen storage diseases (phosphorylase deficiency, phosphofructokinase deficiency)
  • Lipid metabolism disorders
  • Mitochondrial myopathies (electron transport chain defects)
  • Purine nucleotide metabolism abnormalities

These typically present with exercise intolerance, premature fatigability, and markedly reduced maximal oxygen uptake due to impaired muscle oxygen extraction 4.

4. Channelopathies

Disorders of muscle membrane excitability 1, 7:

  • Myotonic disorders (myotonia congenita, paramyotonia congenita)
  • Periodic paralyses (hypokalemic, hyperkalemic)
  • Malignant hyperthermia susceptibility

5. Congenital Myopathies

Structural abnormalities present from birth 7:

  • Central core disease
  • Nemaline myopathy
  • Centronuclear myopathy

Practical Diagnostic Approach

Pattern Recognition by Clinical Phenotype

When contractures predominate over weakness in ambulant patients 6:

  • Consider collagen VI-related myopathies, Emery-Dreifuss muscular dystrophies, SEPN1-related myopathies, FHL1-related myopathies

When exercise intolerance dominates 4:

  • Suspect metabolic myopathies if associated with myoglobinuria
  • Check for oxidative defects if sustained exercise is impaired
  • Evaluate glycolytic pathway if brief high-intensity exercise is limited

When weakness pattern is key 8:

  • Proximal symmetric weakness → inflammatory myopathies, muscular dystrophies
  • Distal weakness → inclusion body myositis, myotonic dystrophy
  • Neck flexor predominance → dermatomyositis, polymyositis

Sports Medicine Classification

For athletic muscle injuries, use the Munich consensus system 9:

  • Type 1: Overexertion-related functional disorders (no fiber tear)
  • Type 2: Neuromuscular functional disorders (no fiber tear)
  • Type 3: Partial structural tears (macroscopic fiber damage)
  • Type 4: (Sub)total tears/tendinous avulsions

Critical Diagnostic Considerations

Common pitfalls to avoid:

  • Do not rely solely on normal muscle enzyme levels—they do not exclude myopathy 10
  • Do not misclassify IBM as PM using older Bohan and Peter criteria 3
  • Do not overlook cardiac and respiratory involvement, which significantly impacts prognosis 8
  • Do not skip muscle imaging and EMG before proceeding to biopsy 6

Essential associated features to assess 8:

  • Myoglobinuria (suggests metabolic myopathy)
  • Myotonia (indicates channelopathy)
  • Cardiac disease (common in dystrophinopathies, Emery-Dreifuss, mitochondrial disorders)
  • Respiratory insufficiency (critical in many progressive dystrophies)

Modern diagnostic hierarchy:

  1. Comprehensive phenotyping (weakness pattern, associated features)
  2. Muscle imaging (MRI/ultrasound)
  3. Electromyography
  4. Genetic testing (increasingly first-line for suspected inherited forms) 8
  5. Muscle biopsy with immunohistochemistry and Western blot 5
  6. Skin biopsy when appropriate (collagen VI disorders)

The shift toward molecular classification reflects that genotype-phenotype correlations now guide treatment selection, particularly with emerging gene therapies and targeted molecular interventions 1, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.